How IL-27 and LAG‑3 control regulatory T cells in autoimmune diabetes
The role of IL-27/Lag3 axis in regulating Foxp3+ regulatory T cell function
This work looks at how two immune signals, IL‑27 and LAG‑3, change regulatory T cells that help prevent the immune system from attacking insulin-producing cells in type 1 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11225120 on NIH RePORTER |
What this research studies
From a patient's perspective, the team is studying how IL‑27 signaling and the surface protein LAG‑3 affect Foxp3+ regulatory T cells that normally keep autoimmune attacks in check. They use laboratory experiments with cells and animal models, plus molecular tools like antibodies and genetic approaches, to see how these pathways change Treg suppressive function. The researchers build on earlier findings linking IL‑27 to Treg activity and aim to resolve conflicting results about whether LAG‑3 helps or hinders Treg control of autoimmune diabetes. Their lab-based work could identify specific molecular steps to target in future therapies.
Who could benefit from this research
Good fit: People with type 1 (autoimmune) diabetes or those at high risk for developing it would be the most relevant group, especially if they can provide blood or other samples for research.
Not a fit: Patients without autoimmune diabetes or those expecting an immediate therapeutic benefit should not expect direct clinical help from this lab-focused work.
Why it matters
Potential benefit: If successful, this could point to new ways to boost or restore regulatory T cells and slow or prevent autoimmune attacks in type 1 diabetes.
How similar studies have performed: Previous studies have shown LAG‑3 and IL‑27 affect regulatory T cells but results have been mixed, so this work follows promising leads while clarifying unresolved questions.
Where this research is happening
Chicago, United States
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Min, Booki — Northwestern University
- Study coordinator: Min, Booki
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.